Skip to main content
. 2022 Sep 27;28(23):5190–5201. doi: 10.1158/1078-0432.CCR-22-2108

Figure 5.

Figure 5. Combination with anti-PD-1 enhances antitumor activity of B7-H6/CD3 ITE. A, B7-H6 and PD-L1 expression on parental HCT-15 and recombinant HCT-15-PD-L1 cell lines. B, B7-H6/CD3 ITE-induced cell lysis (E:T 10:1, 72 hours) in vitro. Each datapoint represents the mean of duplicates, error bars represent the SD. C, PD-L1 expression in HCT-15-PD-L1 xenograft tissue. Antitumor activity of anti-PD-1 monotherapy (D), B7-H6/CD3 ITE monotherapy (E), and B7-H6/CD3 ITE and anti-PD-1 combination therapy (F) in HCT-15-PD-L1 xenograft bearing PBMC-humanized mouse model.

Combination with anti-PD-1 enhances antitumor activity of B7-H6/CD3 ITE. A, B7-H6 and PD-L1 expression on parental HCT-15 and recombinant HCT-15-PD-L1 cell lines. B, B7-H6/CD3 ITE-induced cell lysis (E:T 10:1, 72 hours) in vitro. Each datapoint represents the mean of duplicates, error bars represent the SD. C, PD-L1 expression in HCT-15-PD-L1 xenograft tissue. D-F, Antitumor activity of anti-PD-1 monotherapy (D), B7-H6/CD3 ITE monotherapy (E), and B7-H6/CD3 ITE and anti-PD-1 combination therapy (F) in HCT-15-PD-L1 xenograft bearing PBMC-humanized mouse model.